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Background: The World Health Organization (WHO) and the Institute for Health Metrics and Evaluation (IHME)
have produced numerous global burden of disease (GBD) estimates since the 1990s, using disability-adjusted life-
years (DALYs). Here we attempt to identify studies that have either independent DALY estimates or build on the
work of WHO and IHME, for the WHO European Region, categorize them by scope of disease analysis and
geographic coverage, and briefly compare their methodology (age weighting, discounting and disability
weights). Methods: Google and Google Scholar were used with the search terms ‘DALY’, ‘national burden of
disease’, Member State names and researcher’s names, covering all years. Studies were categorized as: ‘specific’
(fewer than five disease categories or just risk factors for a single country), ‘specific, multicountry’ (fewer than five
disease categories or just risk factors for more than one country), ‘extensive’ (covering five or more but not all
disease categories for one country), ‘full, sub country’ (covering all relevant disease categories for part of one
country) and ‘full, country’ (covering all relevant disease categories for one country). Results: A total of 198 studies
were identified: 143 ‘specific’, 26 ‘specific, multicountry’, 7 ‘extensive’, 10 ‘full, sub country’ and 12 ‘full, country’
[England (1), Estonia (2), France (1), Romania (1), Serbia (1), Spain (3), Sweden (2) and Turkey (1)]. About 5 (20%) of
the 25 examinable ‘extensive’, ‘full, sub country’ and ‘full, country’ studies calculated DALYs using GBD 2010
methodology. Conclusions: Independent burden of diseases studies in Europe have been located, and categorized
by scope of disease analysis and geographic coverage. Methodological choices varied between independent ‘full,
country’ studies.
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Introduction
The burden of disease (BoD) method analyzes the impact ofdisease upon populations through a combination of mortality
and morbidity measures into a single summary statistic of
population health.1 A summary measure frequently used by the
World Health Organization (WHO) and the Institute for Health
Metrics and Evaluation (IHME) is the disability-adjusted life-year
(DALY).2 DALYs quantify disease burden as a health gap; the
difference between a hypothetical ideal state of health and
wellbeing, and the actual observed health status.1 ‘Disability’ in
this context refers to any less than ideal health status.3
DALYs are calculated through the addition of years of life lost
(YLL) and years lost due to disability (YLD) and details of their
calculation are provided elsewhere.3–5 YLL is an incidence-based
measure consisting of the number of deaths multiplied by the
standard life expectancy at the age that each death occurred
(expected life remaining). YLD is a measure of how many years of
healthy life are lost due to time lived in a health status other than
optimal health (i.e. disability). Originally, new incident cases were
used to maintain consistency with YLL, but more recent methods
use prevalence data.4,6–8
YLD calculation relies upon disability weights (DWs) which are
socially derived values based on how the majority of people perceive
living with a disease or condition for a one year period, where 0 is
optimal health and 1 is equivalent to death. These DWs only
represent societal preferences about living with a condition and do
not represent utility, closeness to death, capabilities or the worth of
individuals. DW calculation involves a standardized description of
the health states (e.g. EQ-5 D) and valuation methods such as visual
analogue scale (VAS), time trade-off (TTO), person trade-off (PTO)
or standard gamble (SG). Various DWs have been calculated, e.g. in
the global burden of disease (GBD) studies,9,10 the Netherlands11
and Estonia.12 DWs tend to have reasonably high level of
agreement across populations for most conditions, but valuation
methods vary significantly.13,14
In early DALY estimates two additional social weights, discount-
ing and age weighting, were widely used. With discounting, less
value is applied to future life-years than those lived today, based
on the social preference of a healthy year now rather than at a
later date. Age weighting intends to adjust for altering levels of
dependency with age, as well as possible societal preference for
particular ages of life. Ages 0–38 years were favoured by the appli-
cation of both these social weights.15 However, following consider-
able criticism15–17 both age weighting and discounting have been
dropped from recent WHO/IHME calculations.6–8
As a single number representative of both societal perceptions of
morbidity and objective measures of mortality, DALYs are a clear,
concise and versatile measure of impact which can be applied to
diseases,18 risk factors,19 interventions20 and adverse events.21 They
can also be easily utilized for risk-benefit analysis22 as well as
cost-effectiveness studies.23,24 Since DALYs are rooted in societal
preferences they can also be considered an important step towards
incorporating public opinion in health decision making, and making
decisions more representative of population perspectives.
DALYs were initially conceptualized as the health indicator for the
first GBD study (GBD 1990) which was directed by Christopher
Murray and Alan Lopez under a joint exercise by the WHO and
the World Bank.25,26
This original GBD study produced estimates using both ‘adjusted
DALYs’ (3% discounting and age weighting) and ‘age-weighted
DALYs’ (no discounting, age weighting).25 Following this study
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the WHO6,7 and more recently the IHME2 have produced numerous
GBD updates. The WHO has been producing various versions of
adjusted DALYs, unadjusted DALYs (no discounting, no age
weighting) and discounted DALYs (3% discounting, no age
weighting) for the years 2000–12, but since the GBD 2010 study
unadjusted DALYs have become the established approach.6–8
However, in addition to WHO and IHME estimates many other
independent studies must have been conducted but their number,
scope of disease analysis and methodology remain largely unknown.
Previous literature reviews have provided a snapshot of a vast and
varied literature with considerable variation in the use of discount-
ing, age weighting, DWs, reference life tables, incidence or
prevalence measures and methods handling missing and poorly
coded data.27
In light of the many potential benefits of measuring BoD and the
unknown status and methodology of current independent BoD
studies we decided to identify these studies for the WHO
European Region, and to map out their extent, scope of disease
analysis, geographic coverage and basic methodological choices (in
the case of larger BoD studies). This will provide us with an approxi-
mation of the current level of BoD usage, capacity, and comparabil-
ity, hopefully inspire future research, draw attention to the existing
literature and promote the use of agreed standardized methodology
for local and comparable estimates.
Methods
Due to the different settings in which BoD research is conducted (by
national governments, private sector researchers and academic
settings), and the spread of BoD studies across different types of
journals and databases, it appeared likely that using conventional
search strategies of PubMed, Scopus and similar would
underrepresent this literature. To address this concern and
increase the sensitivity of the search we moved away from specialized
academic databases and instead used Google and Google Scholar as
our search engines.
Three main searches were carried out between April and July
2016, as summarized in table 1. The first used the search terms
‘Member State name’, ‘national burden of disease’ and ‘DALY’ for
each of the 53 Member States in the Region on both Google and
Google Scholar. Unlike the other two searches this first search was
mainly concerned with finding full national/country studies and we
limited our search engines to only show studies since the year 2000.
Since the second GBD study and WHO’s national BoD manual were
not published until 2001 we felt that most studies before this time
would be methodological discussion papers, and that any independ-
ent full national studies in this period should be cited in later
publications.4,9,28
The second search used the search terms ‘burden of disease’ and
‘Member State name’ on Google. The third search used the names of
researchers affiliated with BoD research or methodology, using the
search terms ‘DALY’ and author: ‘full name’ or ‘DALY’ and author:
‘surname’. These names were obtained via personal communication
or from studies found within all three searches.
In addition, reference checks were performed on all accessible
eligible studies. These checks identified many additional publications
that were eligible for inclusion in this review and these are all
included under the applicable search in our results. Reference
checks were especially helpful in locating earlier series of burden-
calculating reports and poorly indexed studies.
Inclusion criteria for studies
Based on this review’s inclusion criteria eligible studies were
identified from the above search hits by reading abstracts or full
texts where available. To be eligible for inclusion in this review,
publications had to satisfy the following inclusion criteria. The
study:
(i) uses the DALY metric, providing DALY estimates for a
population;
(ii) includes a geographic area within the WHO European Region;
(iii) is the original publication of the estimates (or the earliest
located); and
(iv) builds on or modifies WHO and IHME estimates, or is inde-
pendent research that does not include WHO or IHME
estimates.
Publications with original BoD estimates for any part of the
European Region were eligible for inclusion; these included Global
studies,18 as well as cost-effectiveness studies that calculated DALY
rates for a European geographic area as part of their analysis.23,24
Studies that did not meet one or more of the above criteria were not
included in this review.
Classification of studies
A first screening of the studies revealed main differences in the scope
of diseases and geographic coverage. Therefore, in a second step,
studies in this review are classified into five groups based on the
scope of disease analysis and their geographic coverage as follows:
(i) ‘specific’ (covering fewer than five disease categories or just
risk factors for all/part of one European country);
(ii) ‘specific, multicountry’ (covering fewer than five disease
categories or just risk factors for all/parts of more than one
European country);
(iii) ‘extensive’ (covering five or more but not all disease categories
for all/part of one European country);
(iv) ‘full, sub country’ (covering all relevant disease categories and
representative of part of one European country, e.g. a region,
city or population subgroup); and
(v) ‘full, country’ (covering all relevant disease categories and rep-
resentative of the whole of one European country).
The term ‘country’ here can refer to just one constituent country
or territory in the case of larger sovereign countries. This means, e.g.
that a study in Denmark would not need to include the other two
constituent territories (Greenland and the Faroe Islands) to be
categorized as covering a whole country and that a full study in
England, Wales, Scotland, or Northern Ireland would be categorized
as a ‘full, country study’. This decision was made since research
tends to take place at the constituent country or territory level;
e.g. in UK responsibility for health and public health has been
devolved to its constituent countries since 1998.29
The term ‘disease category’ here refers to any of the 23 main cause
categories utilized in recent WHO Global Health Estimates publica-
tions.6,7 In the case of research examining just risk factors (e.g. BoD
caused by environmental exposures) we have classified them as
‘specific’ studies since they focus on a specific category of risk
factors. In doing so we are categorizing studies in terms of com-
pleteness of disease/risk coverage, and are not referring to the quality
or quantity of work involved.
Analysis of methodological choices
Finally we conducted a brief methodological analysis of ‘extensive’,
‘full, sub country’ and ‘full, country’ studies looking at the use of age
weighting, discounting, and DWs (see Supplementary content 1).
They were classified into the four following categories:
(i) ‘adjusted DALYs’ (3% discounting and age weighting);
(ii) ‘discounted DALYs’ (3% discounting, no age weighting);
(iii) ‘age-weighted DALYs’ (no discounting, age weighting); and
(iv) ‘unadjusted DALYs’ (no discounting, no age weighting).
DWs were classed as either GBD DWs (including modified and
updated), or national DWs (Dutch and Estonian).
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Results
Number of studies identified
From the three searches outlined in table 1, including reference
checks, a total of 198 studies were identified that were eligible for
inclusion in this review: 63 from search 1, 51 from search 2 and 84
from search 3.
Study types
About 85% (169/198) of studies looked at a small range of diseases
or just risk factors; of these, 143 involved a population from a single
country (‘specific’) and 26 spanned 2 or more Member States
(‘specific, multicountry’). No multicountry studies looked at more
than two disease categories or risk factors.
The remaining 15% (29/198) of studies looked at a large number
of or all main diseases; of these, 7 looked at 5 or more disease
categories (‘extensive’) and 22 covered all disease categories.
Of the 22 looking at all disease categories, 12 covered a
full country population (‘full, country’) and 10 were for a
population below country representation (‘full, sub country’). A
geographic breakdown of the numbers and types of studies is
shown in figure 2.
Years of publication
As seen in figure 1 the earliest study located was published in 1997,
with a steady increase in the number of studies published each year
up to the latest full year of 2015. This is mainly due to an increase in
the number of ‘specific’ and ‘specific, multicountry’ studies. (Note:
the results for 2016 are not representative of the full year.)
Geographic coverage
Of the 26 specific, multicountry studies, 17 studied all/most of the
WHO European Region (>30 Member States) and 12 of these were
global studies. The other nine studied between two and eight
Member States.
Excluding the 17 specific, multicountry studies that cover all/most
of the Region, publications were still found for about half of
Member States in the Region: 26 of 53. As shown in figure 2
the largest number was in the Netherlands (75), followed by Spain
(21), UK (17), Denmark (15), Belgium (10), Portugal (10), Sweden
(8), Germany (7), France (6), Norway (6), Serbia (6), Italy
(5), Austria (4), Poland (4), Bulgaria (3), Estonia (3), Ireland (3),
Azerbaijan (2), Finland (2), Slovenia (2), Switzerland (2), Albania
(1), Greece (1), Latvia (1), Romania (1) and Turkey (1). [Note: the
sum of these studies adds up to more than the total number of
studies (N = 198) owing to inclusion of the nine smaller ‘specific,
multicountry’ studies under multiple Member States.]
Full, country studies were found for England (1), Estonia (2),
France (1), Romania (1), Serbia (1), Spain (3), Sweden (2) and
Turkey (1).
Methodological choices
Of the 29 ‘extensive’, ‘full, sub country’ and ‘full, country’ studies 25
had enough available data to examine their methodology (two un-
available online, two unexaminable owing to language barriers).
Including published, partly-published and unpublished analysis
some of the 25 studies include more than one of the DALY
categories outlined in our methods section (adjusted DALYs,
discounted DALYs, age-weighted DALYs and unadjusted DALYs).
For these DALY categories, 20 studies (80%) include 1, 4 studies
Table 1 Summary of study searches conducted (April–July 2016)
No. Search engine(s) Search terms Restriction(s) Search numbers
1 Google and Google
Scholar
‘Member State name’, ‘national
burden of disease’, ‘DALY’
Since year 2000 106 searches with 72–538
hits each
2 Google ‘burden of disease’, ‘Member
State name’
Default ‘omit similar
results’ enabled
53 searches with 142–277
hits each
3a Google Scholar ‘DALY’, author: ‘full name’ None >600 researchers 0–104
hits each
3b Google Scholar ‘DALY’, author: ‘surname’ Only first 100 search hits
where >100 hits
>100 researchers 0–6790
hits each
Figure 1 Number of burden of disease studies published each year. Colours of each bar provide a breakdown of the types of studies
conducted each year as follows: light grey (leftmost) bar—specific studies; dark grey (second from left) bar—specific, multicountry studies;
very dark grey (third from left) bar—extensive studies; darkest grey (fourth from left) bar—full, sub country studies; black (fifth from left)
bar—full, country studies; numbered white bar with a black outline (rightmost)—total number of BoD studies
aPlease note that the online searches for this review were conducted between April and July 2016.
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(16%) include 2 and 1 study (4%) includes 3 DALY categories
(31 DALY category estimates in total). Including studies under all
relevant categories: 17 studies (68%) calculated adjusted DALYs, 3
studies (12%) calculated discounted DALYs, 2 studies (8%)
calculated age-weighted DALYs and 9 studies (36%) calculated
unadjusted DALYs.
In total five studies (20%) used national DWs, with two using
Estonian weights and three using Dutch weights. Four of these used
unadjusted DALYs, and all five were published before the GBD
2010 study when this approach became the norm for GBD
estimatimation.6,8
In total five (20%) used unadjusted DALYs with GBD DWs and
four of these were published before the GBD 2010 study.
Discussion
This paper has mapped the extent, scope of disease analysis and
geographic coverage of BoD research for the WHO European
Region until mid-2016. Since this date additional studies may
have been published, one example being the comprehensive
Scottish BoD study.30
We were surprised to find nearly 200 BoD studies for the Region,
but these were mainly specific in focus, examining a limited number
of diseases or just risk factors. About 85% of publications used
DALYs for these specific research topics. Nevertheless, this illustrates
that BoD methods are widely used and valued throughout the
Region by numerous researchers. Most of the publications
examining all disease categories were conducted in Spain, with a
total of seven: three full, country studies and four full, sub
country studies. Others, such as a full, country study in France or
full, sub country studies in Azerbaijan and Portugal, remain rarely
cited.
The majority of BoD publications comes from the Netherlands,
where the methodology is highly integrated into national disease
reporting in many different specific areas.31,32 However, these
include only three extensive studies and no full studies. This
approach of using BoD analysis in a fragmented topic-specific
manner (seen in the Netherlands and across the European Region)
is generally not ideal, as it tends to overestimate the impact of
studied conditions and excludes other important diseases and risk
factors. Only full BoD studies avoid large over-attributions of
burden to specific individual conditions and give more accurate,
balanced estimates.33 In our view, full, country and full, sub
country studies provide the most robust data for policy.
Our analysis shows that BoD studies were carried out primarily in
the western part of the Region (see figure 2) and highlights areas
without independent BoD publications. We hope that these gaps in
the literature will soon be addressed as they would allow for the use
of local data for the estimation of BoD without the need to ‘borrow
strength’ from data of other countries.
While this review makes important observations it does have a
number of limitations. First, the terminology of search terms and
their combinations was intentionally narrow—‘burden of disease’
was used but ‘disease burden’ was not. A preliminary test showed
that the latter phrase was too unspecific and yielded too many
studies that in the end were not dealing with BoD using DALYs.
Longer, more robust, search terms could have been used, as well as
search engines other than Google and Google Scholar. However,
given the large number of searches and reference checks
conducted we consider these limitations minor. A second and
more serious limitation was that the search was only conducted in
the English language and this language bias may explain the Western
European concentration of publications observed. Finally, not all
research is published online. This was in fact the case with two of
the full, country studies in this review which were only cited and
Figure 2 Map of the WHO European Region showing the total number of burden of disease studies conducted for each Member State and
the most comprehensive type of study for each. Colours illustrate the most comprehensive type of study for each Member State as follows:
light grey shading with black text—specific studies (including multicountrya); dark grey shading with black text—extensive study; dark grey
shading with white text—full, sub country study; black shading with white text—full, country studyb
aPlease note that specific multicountry studies that cover over half the Member States (N =17) are not included on this map.
bPlease note that the full, country study for UK only covers England, not the whole of UK.
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described in other available sources. The extent of this unpublished
BoD research remains unknown.
Given our findings, the next step could be to analyze methodo-
logical differences in more detail, with the aim of harmonizing
methods in Europe and making BoD estimates more accessible to
policy-makers. Recent collaborative efforts between WHO and
IHME have already made progress towards this aim,34 including
establishing the European Burden of Disease Network (EBoDN) in
September 2016.35,36 This is the first health information network of
its kind and operates under the umbrella of the WHO European
Health Information Initiative,37 which guides all health information
activities of the WHO Regional Office for Europe.
Our analysis highlights that more countries should embrace the
BoD approach in order to enhance local and comparable estimates
across the Region and inform national health policy-makers. The
variations in methodology in the studies identified confirms the
need for the establishment of the EBoDN, which aims to harmonize
BoD methods across the Region and engage all Member States, in
particular through the development of a national BoD manual that
will guide national researchers to perform such studies at the country
level. This collaboration in BoD analysis and evidence-informed
research is paving the way for better policy-making in the interest
of public health and wellbeing.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
 A total of 198 relevant BoD publications were identified: 143
‘specific’, 26 ‘specific, multicountry’, 7 ‘extensive’, 10 ‘full,
sub country’ and 12 ‘full, country’.
 Over half of all BoD publications were in the Netherlands
(75), Spain (21) and UK (17).
 Full, country studies were found for England (1), Estonia
(2), France (1), Romania (1), Serbia (1), Spain (3), Sweden
(2) and Turkey (1).
 Extensive and full studies varied in terms of methodological
choices (age weighting, discounting, and disability weights),
most used those of the original GBD study.
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